66th ASH Annual Meeting: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs

Symposia: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Combination therapy, Apoptosis, Fundamental Science, Translational Research, MPN, Drug development, Bispecific Antibody Therapy, Genomics, Chronic Myeloid Malignancies, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Non-Biological therapies, Metabolism, Myeloid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Pathogenesis

Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

Moderators:

Yana Pikman, MD, Dana-Farber Cancer Institute and Boston Children's Hospital and Paolo Gallipoli, MD/PhD, ARRAY(0xf1bc4c0)

Disclosures:

Gallipoli: Astellas: Honoraria; GSK: Other: Spouse works for GSK.

2:45 PM

823

Crebbp Inhibition Potentiates JAK2 Inhibition in Post-MPN Acute Myeloid Leukemia

Kalay Bertulfo, MS, MA, MPhil¹, Hannah Miller¹^*, Ryan Najac¹^*, Juan Carlos Castelan²^*, Cindy Ma¹^*, Koen Debackere, MD, PhD¹^*, Wenbin Xiao, MD, PhD³, Raajit Rampal, MD, PhD⁴, Ross L Levine, MD⁴, Chao Lu, PhD⁵^*, Adolfo A. Ferrando, MD, PhD⁶^* and Teresa Palomero, PhD^1,7

¹Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY
²Columbia University Irving Medical Center, New York, NY
³Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY
⁶Regeneron Pharmaceuticals Inc., Tarrytown, NY
⁷Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY

3:00 PM

824

Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager

Ashley Varkey, DO^1,2, Manpreet Bariana²^*, Elena Cassella²^*, Shaina Anuncio²^*, Mark Batistick²^*, Sonia Sequeira, PhD³^*, Mahiuddin Ahmed, PhD⁴^* and Johannes Zakrzewski, MD^1,2,5

¹Department of Pediatrics, Hackensack University Medical Center, Hackensack
²Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ
³Vitruviae LLC, Nutley, NJ
⁴Vitruviae LLC, Verona, NJ
⁵Department of Oncology, Georgetown University, Washington DC

3:15 PM

825

The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia

Nicole L Michmerhuizen, PhD¹, Emily Heikamp, MD, PhD², Masayuki Umeda, MD, PhD³, Ilaria Iacobucci, PhD⁴, Bright Arthur¹^*, Danika Di Giacomo, PhD¹^*, Ryan Hiltenbrand¹^*, Sandi Radko-Juettner, PhD¹^*, Pablo Portola¹^*, Aurelie Claquin¹^*, Bappaditya Chandra, PhD⁵^*, David W Baggett⁵^*, Hongling Huang, PhD⁶^*, Peipei Zhou, PhD⁶^*, Lingyun Long, PhD⁷^*, Hao Shi⁶^*, Yu Sun⁶^*, Evangelia K Papachristou, PhD⁸^*, Chandra Sekhar Reddy Chilamakuri⁸^*, Francisca N. de L. Vitorino⁹^*, Joanna M Gongora⁹^*, Clive S D'Santos, PhD¹⁰^*, Benjamin A Garcia, PhD¹¹^*, Richard W Kriwacki, PhD⁵^*, Hongbo Chi, PhD¹²^*, Alex Kentsis, MD, PhD¹³, Scott A Armstrong, MD, PhD¹⁴, Jeffery M Klco, MD, PhD¹ and Charles G. Mullighan, MBBS, MSc, MD¹

¹Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
²Dana Farber Cancer institute, Boston, MA
³Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN
⁴St. Jude Children's Research Hospital, Memphis, TN
⁵Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN
⁶Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN
⁷Department of Immunology, St Jude Children's Research Hospital, Memphis, TN
⁸Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
⁹Department of Biochemistry and Molecular Biophysics, Washington University in St. Louis, St. Louis, MO
¹⁰Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, GBR
¹¹Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO
¹²Department of Immunology, St. Jude ChildrenS Research Hospital, Memphis, TN
¹³Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁴Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

3:30 PM

826

REM-422, a Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity As Monotherapy and in Combination with Standards of Care in Preclinical Models of AML

Samantha Levin-Furtney, MSc^*, Michael Thomas^*, Alycen M. Harney^*, Mengge Shan^*, Alexander Ivliev^*, Adam Stefek^*, Michael Cameron^*, Sudeep Prajapati^*, Michael Seiler^*, Dominic Reynolds^*, Silvia Buonamici and Charles Kung^*

Remix Tx, Watertown, MA

3:45 PM

827

Targeting Mitochondrial Metabolism to Promote Viral Mimicry and Type I Interferon Response in Acute Myeloid Leukemia

Nithya Balasundaram, PhD¹, Hernan Tirado Andreas, MSc²^*, Fleur Leguay, BSc²^* and Nick Van Gastel, PhD²^*

¹Laboratory of Cellular Metabolism and Microenvironment, De Duve Institute, UC Louvain, Brussels, Brussels, Belgium
²Laboratory of Cellular Metabolism and Microenvironment, De Duve Institute, UC Louvain, Brussels, Belgium

4:00 PM

828

CCRL2 As a Novel Target in Acute Erythroid Leukemia

Nour Naji, MD¹^*, Taha Ahmedna^1,2^*, Theodora Chatzilygeroudi, MD¹^*, Tushar Nichakawade²^*, Sean Lee²^*, Brandy Perkins¹^*, Chen Lossos, MD³^*, Bogdan Paun, MD¹^*, Evangeline Watson²^*, Rena R. Xian, MD³, Styliani Karanika⁴^*, Rick Jones¹^*, Suman Paul, MBBS, PhD^1,2 and Theodoros Karantanos, MD, PhD⁵

¹Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
²Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore
³Division of Hematopathology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
⁴Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
⁵Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

604.O2.6 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs